Special Issue

Diabetes Mellitus: Promising Molecules, Drug Modification, Formulations, and Therapy

Message from the Guest Editor

Diabetes mellitus is a complex and heterogeneous disease that can affect people at different stages of life. Despite the availability of various therapeutic agents in modern medicine, maintaining adequate levels of glycemic control is still a challenge. It requires improvements in pharmacotherapy by means of agents with new mechanisms of action and/or making improvements to existing drugs by creating innovative delivery systems. Thus, this Special Issue aims to collect articles that are devoted to the study of the pharmacological properties of chemical compounds that have new, not yet applicable in medicine, mechanisms of hypoglycemic action. It also welcomes papers that attend to the creation of delivery systems and to other modifications made to drugs that are already available on the pharmaceutical market. In this Special Issue, research areas may include (but not limited to) the following:

- New therapy targets for T2DM treatment;
- Drug discovery and development for diabetes treatments:
- T2DM's complications treatment:
- Drug delivery systems for diabetes treatments;
- Pharmaceutical formulation design for diabetes treatments.

Guest Editor

Dr. Mikhail V. Khvostov

Laboratory of Pharmacological Researches, N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry (NIOCH SB RAS), Novosibirsk 630090, Russia

Deadline for manuscript submissions

closed (20 September 2024)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/167306

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

